Cetuximab biosimilar (R-Pharm)

西妥昔单抗生物类似药 (R-Pharm)

Report date: 2026/03/04 20:01:44

Base Information

Drug NameCetuximab biosimilar (R-Pharm)

Drug Alias Name西妥昔单抗生物仿制药 (R-Pharm)RPH-002

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists

TargetsEpidermal growth factor receptor erbB1

Therapy Area/IndicationsHead and Neck NeoplasmsPancreatic NeoplasmsSquamous Cell Carcinoma of Head and Neck

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUzbekistanRussian Federation

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesR-Pharm Jsc

China Registration ClassN/A

Active CompaniesR-Pharm Jsc

Inactive CompaniesN/A

Active IndicationsHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and Neck

Inactive IndicationsPancreatic Neoplasms

ATC CodeL01XC06